Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Related Citations for PubMed (Select 9643862)

1.

Public health implications of antiretroviral therapy and HIV drug resistance.

Wainberg MA, Friedland G.

JAMA. 1998 Jun 24;279(24):1977-83.

PMID:
9643862
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

HIV resistance to antiviral drugs: public health implications.

Wainberg MA, Cameron DW.

Drug Resist Updat. 1998;1(2):104-8.

PMID:
16904396
4.

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.

Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ.

J Infect Dis. 2003 Feb 15;187(4):683-6. Epub 2003 Jan 29.

5.

Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.

Murray JM.

J Infect Dis. 2003 Oct 15;188(8):1258; author reply 1258-9. No abstract available.

6.

HAART won't completely eradicate HIV in semen.

[No authors listed]

AIDS Alert. 1999 May;14(5):56-7.

PMID:
11366401
7.

Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.

Goudsmit J, Weverling GJ, van der Hoek L, de Ronde A, Miedema F, Coutinho RA, Lange JM, Boerlijst MC.

AIDS. 2001 Nov 23;15(17):2293-301.

PMID:
11698703
8.

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D.

JAMA. 2001 Jul 11;286(2):196-207.

PMID:
11448283
9.

Emergence of HIV-1 drug resistance during antiretroviral treatment.

Rong L, Feng Z, Perelson AS.

Bull Math Biol. 2007 Aug;69(6):2027-60. Epub 2007 Apr 21.

PMID:
17450401
10.

Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission.

Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, Cohen MS.

AIDS. 1998 Oct 22;12(15):F181-9.

PMID:
9814860
11.

Drug-resistant human immunodefiency virus.

Kozal MJ.

Clin Microbiol Infect. 2009 Jan;15 Suppl 1:69-73. doi: 10.1111/j.1469-0691.2008.02687.x. Review.

12.

Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.

Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sönnerborg A, Nachega JB.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S101-6. doi: 10.1093/infdis/jit108.

13.

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Coté P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP.

AIDS. 2000 Jan 28;14(2):F17-23.

PMID:
10708278
14.

Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.

Booth CL, Geretti AM.

J Antimicrob Chemother. 2007 Jun;59(6):1047-56. Epub 2007 Apr 19. Review.

15.

Epidemiological aspects of transmitted HIV drug resistance.

Girardi E.

Scand J Infect Dis Suppl. 2003;106:17-20. Review.

PMID:
15000576
17.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
18.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

19.

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD.

JAMA. 1998 Jun 24;279(24):1984-91. Review.

PMID:
9643863
20.

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG.

AIDS. 2006 Jan 9;20(2):223-31.

PMID:
16511415
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk